ADVANCELL
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.
ADVANCELL
Industry:
Biotechnology Clinical Trials Oncology Pharmaceutical
Founded:
2019-01-01
Address:
Sydney, New South Wales, Australia
Country:
Australia
Website Url:
http://www.advancell.com.au
Total Employee:
11+
Status:
Active
Total Funding:
14.56 M USD
Technology used in webpage:
Google Maps CrUX Dataset CrUX Top 10m
Similar Organizations
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Iroko Pharmaceuticals
Iroko Pharmaceuticals is a global specialty pharmaceutical company dedicated to advancing the science of analgesia.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Current Advisors List
Investors List
Morningside Venture Investments
Morningside Venture Investments investment in Series B - AdvanCell
NSW Health
NSW Health investment in Grant - AdvanCell
Official Site Inspections
http://www.advancell.com.au Semrush global rank: 10.01 M Semrush visits lastest month: 282
- Host name: syn342.syd4.hostyourservices.net
- IP address: 43.250.140.49
- Location: Australia
- Latitude: -33.494
- Longitude: 143.2104
- Timezone: Australia/Sydney
More informations about "AdvanCell"
AdvanCell - Crunchbase Company Profile & Funding
AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer treatment.See details»
ADVANCELL PTY LIMITED Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for ADVANCELL PTY LIMITED of Sydney, NEW SOUTH WALES. Get the latest business insights from Dun & …See details»
AdvanCell Isotopes Pty Ltd - The Org
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment.See details»
AdvanCell Proudly Announces $18M in Federal Funding from the …
AdvanCell is collaborating with world-leading experts in Australia and globally, underpinning the transformative nature of the important clinical research.See details»
PRESS RELEASE Therapies for the Treatment of Cancer
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer Brisbane, Australia and Indianapolis, USA – February …See details»
Biotech aiming to treat 9 cancers secures $177m in …
Feb 14, 2025 The trio will join existing directors Bill Ferris AC, Anthony Aiudi, Kevin Cameron, and Andrew Adamovich. “We are delighted to support AdvanCell’s growth and play a role in its remarkable journey through leading …See details»
AdvanCell Closes A$18M Series B Funding Led by Morningside
AdvanCell has a world-class team and is honoured to be advised by an outstanding Board of Directors and Scientific Advisory Board. For more information visit www.advancell.com.au …See details»
Bringing Targeted Alpha - AdvanCell
About AdvanCell AdvanCell is a radiopharmaceutical company that works with technology to develop a revolutionary cancer treatment called Targeted Alpha Therapy, providing new hope for patients with untreatable cancers. The major …See details»
A world-first alpha isotope generator - The Index Project
AdvanCell is an Australian clinical stage radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy. AdvanCell's Generator is a world-first alpha isotope generator which …See details»
AdvanCell - Company Profile
About AdvanCell is a clinical stage radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform …See details»
AdvanCell Announces the Launch of its Flagship Facility to Support ...
AdvanCell secured a long-term lease for a purpose-built facility fully equipped with clean rooms and infrastructure for manufacturing radiopharmaceuticals - providing the platform to …See details»
Targeting a new generation of radiopharmaceuticals with AdvanCell
AdvanCell is an Australian-based clinical-stage radiopharmaceutical company that is developing a range of novel therapies to boost cancer survival rates and improve patients’ quality of life.See details»
Contact - AdvanCell
AdvanCell’s in-house manufacturing team and infrastructure ensures CMC development to meet FDA requirements.See details»
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance ...
Feb 10, 2025 Brisbane, Australia and Indianapolis, USA – February 10, 2025 AdvanCell, a clinical stage radiopharmaceutical company specializing in targeted alpha therapies, today …See details»
News - AdvanCell
In the Press Andrew is a founder and Managing Director of AdvanCell Isotopes, and a founder and Director of Riverland Capital, a private investment firm. Julian has over 20 years expertise …See details»
Australian radiopharma players take on big pharma - forbes.com.au
May 26, 2025 AdvanCell is one of at least three Australian companies that say they can do it better and are gunning for a piece of Novartis’s action. The field is being hotly contested. In …See details»
AdvanCell Closes A$18M Series B Funding Led by Morningside
Aug 24, 2022 AdvanCell, an Australian radiopharmaceutical company focused on Targeted Alpha Therapy, announces the closing of a financing round led by Morningside.See details»
Technology - AdvanCell
Proprietary ²¹²Pb production technology provides access to an unmatched supply of alpha isotopes to accelerate clinical development of a portfolio of targeted alpha therapies.See details»
Richlands DP Manufacturing PR-FINAL
AdvanCell continues to collaborate with manufacturing partners to supply investigational products for its clinical programs and looks forward to expanding clinical trial sites in Australia and globally.See details»
Partners - AdvanCell
AdvanCell would like to acknowledge the National Isotope Development Center (NIDC) and the DOE U.S. Department of Energy Isotope Program (DOE IP), which funds the NIDC, as the …See details»